ERBB2 and cancer: Thus, the high percentage of SAβ-gal positive cancer cells within our HER2+ breast cancer samples might suggest that oncogenic HER2-induced senescence results in a secretome that can inhibit the recruitment of immune cells and thereby reduced elimination of the senescent cells, leading to accumulation of senescent cells within these tumors.